Trial · NCT00986583
Effect of Succinylcholine on Patients Using Statins
NCT00986583, Not applicable, Completed, The Cleveland Clinic; results first posted 2016-08-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Succinylcholine on Patients Using Statins. Trials, record NCT00986583. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00986583
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Succinylcholine on Patients Using Statins
- NCT number
- NCT00986583
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 70 participants, actual
- Lead sponsor
- The Cleveland Clinic
- Conditions
- Pain
- Interventions
- Succinylcholine
- First posted
- 2009-09-30
- Last updated
- 2016-10-03
- Results first posted
- 2016-08-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Plasma Myoglobin Concentration | induction, 5 minutes after administration, 20 minutes and 24 hours post operatively | |
| Secondary | Muscle Pain | 2 and 24 hours postoperatively | verbal rating scale score and the pain score both at 2 and 24 hours postoperatively. The verbal rating scale score ranges from 0 (no pain) to 100 (worst pain imaginable). The pain score ranges from 0 to 3: 0 none; 1 muscle stiffness or pain in the nape of the neck, shoulders, and chest; 2 muscle stiffness and pain requiring analgesia; and 3 incapacitating generalized muscle stiffness or pain. |
| Secondary | Serum Potassium Concentration | At 5 and 20 min after succinylcholine | |
| Secondary | Change in Plasma Creatine Phosphokinase (CK) Concentration From 2 to 24 Hours Postoperatively | 2 and 24 hours postoperatively | Change in plasma creatine phosphokinase (CK) concentration from 2 to 24 hours postoperatively |
| Secondary | Duration of Succinylcholine Block | intraoperative: from succinylcholine administration | Time required to reach maximum block by succinylcholine after succinylcholine administration. |
| Secondary | Fasciculation | postoperative | The fasciculation ranges from 0 to 3: 0 none; 1 small movements around eyes and fingers; 2 moderate movements in face, neck, fingers, and trunk; and 3 vigorous movements in trunk and extremities. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Plasma Myoglobin Concentration | induction, 5 minutes after administration, 20 minutes and 24 hours post operatively | ug/l | MEDIAN | |
| SECONDARY | Muscle Pain | 2 and 24 hours postoperatively | participants | NUMBER | |
| SECONDARY | Serum Potassium Concentration | At 5 and 20 min after succinylcholine | Two patients in non-statin group had missing value at 20 minute. | mEq/l | MEDIAN |
| SECONDARY | Change in Plasma Creatine Phosphokinase (CK) Concentration From 2 to 24 Hours Postoperatively | 2 and 24 hours postoperatively | Two patients in the nonstatin group had missing CK value at 2 hour | units/l | MEDIAN |
| SECONDARY | Duration of Succinylcholine Block | intraoperative: from succinylcholine administration | minute | MEDIAN | |
| SECONDARY | Fasciculation | postoperative | participants | NUMBER |
Source ClinicalTrials.gov
Results by group52
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Plasma Myoglobin Concentration | Statin Use Group | Measurement time = induction (0 minute) | 46 | Inter-Quartile Range 40 to 59 | ug/l |
| Plasma Myoglobin Concentration | Non Statin Use | Measurement time = induction (0 minute) | 39 | Inter-Quartile Range 29 to 49 | ug/l |
| Plasma Myoglobin Concentration | Statin Use Group | Measurement time = 5 minute | 71 | Inter-Quartile Range 47 to 96 | ug/l |
| Plasma Myoglobin Concentration | Non Statin Use | Measurement time = 5 minute | 49 | Inter-Quartile Range 31 to 75 | ug/l |
| Plasma Myoglobin Concentration | Statin Use Group | Measurement time = 20 minute (primary) | 77 | Inter-Quartile Range 49 to 112 | ug/l |
| Plasma Myoglobin Concentration | Non Statin Use | Measurement time = 20 minute (primary) | 47 | Inter-Quartile Range 35 to 79 | ug/l |
| Plasma Myoglobin Concentration | Statin Use Group | Measurement time = 24 hour | 137 | Inter-Quartile Range 86 to 342 | ug/l |
| Plasma Myoglobin Concentration | Non Statin Use | Measurement time = 24 hour | 95 | Inter-Quartile Range 57 to 210 | ug/l |
| Muscle Pain | Statin Use Group | VRS score at 2 hour: 0 (no pain) | 34 | participants | |
| Muscle Pain | Non Statin Use | VRS score at 2 hour: 0 (no pain) | 26 | participants |
1 to 10 of 52Source ClinicalTrials.gov
See all 52 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Statin Use Group | 38 | |
| Overall Study | STARTED | Non Statin Use | 32 | |
| Overall Study | COMPLETED | Statin Use Group | 38 | |
| Overall Study | COMPLETED | Non Statin Use | 32 | |
| Overall Study | NOT COMPLETED | Statin Use Group | 0 | |
| Overall Study | NOT COMPLETED | Non Statin Use | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Statin Users | ||
| Total, all-cause mortality | Nonstatin Users | ||
| Total, other adverse events | Statin Users | 0 | 38 |
| Total, other adverse events | Nonstatin Users | 0 | 32 |
| Total, serious adverse events | Statin Users | 0 | 38 |
| Total, serious adverse events | Nonstatin Users | 0 | 32 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Statin Users vs Nonstatin Users: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00986583
GET https://conductscience.org/api/trials/v1/NCT00986583/results?page=2